Association between SARS-CoV-2 variants and post COVID-19 condition: findings from a longitudinal cohort study in the Belgian adult population.


Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
08 Nov 2023
Historique:
received: 01 04 2023
accepted: 04 11 2023
medline: 10 11 2023
pubmed: 9 11 2023
entrez: 8 11 2023
Statut: epublish

Résumé

While many studies on the determinants of post-COVID-19 conditions (PCC) have been conducted, little is known about the relationship between SARS-CoV-2 variants and PCC. This study aimed to assess the association between different SARS-CoV-2 variants and the probability of having PCC three months after the infection. This study was a longitudinal cohort study conducted between April 2021 and September 2022 in Belgium. In total, 8,238 adults with a confirmed SARS-CoV-2 infection were followed up between the time of their infection and three months later. The primary outcomes were the PCC status three months post infection and seven PCC symptoms categories (neurocognitive, autonomic, gastrointestinal, respiratory, musculoskeletal, anosmia and/or dysgeusia, and other manifestations). The main exposure variable was the type of SARS-CoV-2 variants (i.e. Alpha, Delta, and Omicron), extracted from national surveillance data. The association between the different SARS-CoV-2 variants and PCC as well as PCC symptoms categories was assessed using multivariable logistic regression. The proportion of PCC among participants infected during the Alpha, Delta, and Omicron-dominant periods was significantly different and respectively 50%, 50%, and 37%. Participants infected during the Alpha- and Delta-dominant periods had a significantly higher odds of having PCC than those infected during the Omicron-dominant period (OR = 1.61, 95% confidence interval [CI] = 1.33-1.96 and OR = 1.73, 95%CI = 1.54-1.93, respectively). Participants infected during the Alpha and Delta-dominant periods were more likely to report neurocognitive, respiratory, and anosmia/dysgeusia symptoms of PCC. People infected during the Alpha- and Delta-dominant periods had a higher probability of having PCC three months after infection than those infected during the Omicron-dominant period. The lower probability of PCC with the Omicron variant must also be interpreted in absolute figures. Indeed, the number of infections with the Omicron variant being higher than with the Alpha and Delta variants, it is possible that the overall prevalence of PCC in the population increases, even if the probability of having a PCC decreases.

Sections du résumé

BACKGROUND BACKGROUND
While many studies on the determinants of post-COVID-19 conditions (PCC) have been conducted, little is known about the relationship between SARS-CoV-2 variants and PCC. This study aimed to assess the association between different SARS-CoV-2 variants and the probability of having PCC three months after the infection.
METHODS METHODS
This study was a longitudinal cohort study conducted between April 2021 and September 2022 in Belgium. In total, 8,238 adults with a confirmed SARS-CoV-2 infection were followed up between the time of their infection and three months later. The primary outcomes were the PCC status three months post infection and seven PCC symptoms categories (neurocognitive, autonomic, gastrointestinal, respiratory, musculoskeletal, anosmia and/or dysgeusia, and other manifestations). The main exposure variable was the type of SARS-CoV-2 variants (i.e. Alpha, Delta, and Omicron), extracted from national surveillance data. The association between the different SARS-CoV-2 variants and PCC as well as PCC symptoms categories was assessed using multivariable logistic regression.
RESULTS RESULTS
The proportion of PCC among participants infected during the Alpha, Delta, and Omicron-dominant periods was significantly different and respectively 50%, 50%, and 37%. Participants infected during the Alpha- and Delta-dominant periods had a significantly higher odds of having PCC than those infected during the Omicron-dominant period (OR = 1.61, 95% confidence interval [CI] = 1.33-1.96 and OR = 1.73, 95%CI = 1.54-1.93, respectively). Participants infected during the Alpha and Delta-dominant periods were more likely to report neurocognitive, respiratory, and anosmia/dysgeusia symptoms of PCC.
CONCLUSIONS CONCLUSIONS
People infected during the Alpha- and Delta-dominant periods had a higher probability of having PCC three months after infection than those infected during the Omicron-dominant period. The lower probability of PCC with the Omicron variant must also be interpreted in absolute figures. Indeed, the number of infections with the Omicron variant being higher than with the Alpha and Delta variants, it is possible that the overall prevalence of PCC in the population increases, even if the probability of having a PCC decreases.

Identifiants

pubmed: 37940843
doi: 10.1186/s12879-023-08787-8
pii: 10.1186/s12879-023-08787-8
pmc: PMC10634063
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

774

Subventions

Organisme : Sciensano
ID : internal funding

Informations de copyright

© 2023. The Author(s).

Références

Pathogens. 2022 Feb 19;11(2):
pubmed: 35215212
Am J Epidemiol. 2023 Jan 6;192(1):6-10
pubmed: 36222655
PLoS One. 2023 Feb 22;18(2):e0281429
pubmed: 36812215
Ann Med. 2022 Dec;54(1):1473-1487
pubmed: 35594336
Vaccine. 2022 May 11;40(22):3027-3037
pubmed: 35459558
Nat Commun. 2022 Nov 30;13(1):7363
pubmed: 36450749
J Mol Med (Berl). 2020 Jul;98(7):947-954
pubmed: 32535768
Pathogens. 2022 Jun 25;11(7):
pubmed: 35889971
Int J Infect Dis. 2020 Nov;100:327-332
pubmed: 32920235
Ann Med Surg (Lond). 2022 Aug;80:103995
pubmed: 35721785
Infection. 2021 Dec;49(6):1163-1186
pubmed: 34319569
J Infect Dis. 2023 Sep 04;:
pubmed: 37665981
Int J Environ Res Public Health. 2021 Mar 05;18(5):
pubmed: 33807869
Lancet Digit Health. 2023 Jul;5(7):e421-e434
pubmed: 37202336
Arch Public Health. 2022 Apr 13;80(1):118
pubmed: 35418097
Clin Infect Dis. 2022 Aug 24;75(1):e1120-e1127
pubmed: 34487522
Bull World Health Organ. 2001;79(4):373-4
pubmed: 11357217
BMJ Glob Health. 2021 Sep;6(9):
pubmed: 34580069
BMC Infect Dis. 2022 Nov 11;22(1):839
pubmed: 36368977
Lancet. 2022 Jun 18;399(10343):2263-2264
pubmed: 35717982
J Clin Med. 2021 Nov 25;10(23):
pubmed: 34884216
Arch Public Health. 2022 Jun 4;80(1):151
pubmed: 35659364

Auteurs

Huyen Nguyen Thi Khanh (HN)

Department of Epidemiology and public health, Sciensano, Brussels, Belgium. khanhhuyenhnhuph@gmail.com.
Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium. khanhhuyenhnhuph@gmail.com.

Laura Cornelissen (L)

Department of Epidemiology and public health, Sciensano, Brussels, Belgium.

Diego Castanares-Zapatero (D)

Belgian Health Care Knowledge Centre (KCE), Brussels, Belgium.

Robby De Pauw (R)

Department of Epidemiology and public health, Sciensano, Brussels, Belgium.
Department of Rehabilitation Sciences, Ghent University, Ghent, Belgium.

Dieter Van Cauteren (D)

Department of Epidemiology and public health, Sciensano, Brussels, Belgium.

Stefaan Demarest (S)

Department of Epidemiology and public health, Sciensano, Brussels, Belgium.

Sabine Drieskens (S)

Department of Epidemiology and public health, Sciensano, Brussels, Belgium.

Brecht Devleesschauwer (B)

Department of Epidemiology and public health, Sciensano, Brussels, Belgium.
Department of Translational Physiology, Infectiology and Public Health, Ghent University, Ghent, Belgium.

Karin De Ridder (K)

Department of Epidemiology and public health, Sciensano, Brussels, Belgium.

Rana Charafeddine (R)

Department of Epidemiology and public health, Sciensano, Brussels, Belgium.

Pierre Smith (P)

Department of Epidemiology and public health, Sciensano, Brussels, Belgium.
Institute of Health and Society (IRSS), Université catholique de Louvain, Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH